Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hycroft Mining Holding Corporation Class A Common Stock (HYMC) vs Relay Therapeutics Inc. Common Stock (RLAY) Price & Performance

Hycroft Mining Holding Corporation Class A Common StockTrade
Relay Therapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Hycroft Mining Holding Corporation Class A Common Stock vs Relay Therapeutics Inc. Common Stock — how do they compare? Hycroft Mining Holding Corporation Class A Common Stock trades at $16.72 (market cap $1.64B), while Relay Therapeutics Inc. Common Stock trades at $16.91 (market cap $3.81B). The key difference: Relay Therapeutics Inc. Common Stock is far larger — about 2.3× Hycroft Mining Holding Corporation Class A Common Stock's market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, Hycroft Mining Holding Corporation Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hycroft Mining Holding Corporation Class A Common Stock for 0 Days and Relay Therapeutics Inc. Common Stock for 5 Days on average.

HYMCRLAY
Market Cap
$1.64B$3.81B
Volume
1,750,0981,706,150
Sector
Basic MaterialsHealth
52-Week High
$55.74$20.75
52-Week Low
$6.75$6.05
Typical Hold Time
0 Days5 Days
Enterprise Value
$1.42B$2.93B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hycroft Mining Holding Corporation Class A Common Stock

No Aura AI signal available yet.

Relay Therapeutics Inc. Common Stock

Relay Therapeutics (RLAY) trades at $17.36, down 3.45% today, with technical indicators showing bearish momentum. The company remains in clinical-stage development with negative profitability metrics, including a -2,763.64% net income margin and -$276.48M net loss for 2025. Recent Q2 2026 earnings missed expectations with a loss of $0.41 per share, though the company continues advancing its oncology pipeline with Phase 3 trials planned for 2027.

Despite unanimous analyst buy ratings and a $26.25 consensus price target representing 51% upside, RLAY faces significant execution risk as a pre-revenue biotech. The stock's bearish technical setup and persistent cash burn require careful risk management, though institutional accumulation and AI-driven drug discovery platform provide long-term potential.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HYMC
100% Buy0% Sell
Avg holding period · 0 Days
RLAY

No sentiment data available yet.

About Hycroft Mining Holding Corporation Class A Common Stock

Hycroft Mining Holding Corporation is a US mining company that owns and operates the Hycroft Mine, a gold and silver deposit in northern Nevada, producing and selling gold and silver from open-pit mining operations.

Read more on HYMC →

About Relay Therapeutics Inc. Common Stock

Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.

Read more on RLAY →